Phase 2 N=18 Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds
N/A N=14 Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
Covid19 · Respiratory Function Loss · Coronavirus Infection
Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374
Phase 2 N=19 Electrical Stimulation for Critically Ill Post-Covid-19 Patients
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
N/A N=90 Psychological Symptoms and Families of COVID-19 Patients
Family Members · Post Intensive Care Unit Syndrome · Post Traumatic Stress Disorder
Primary: Symptoms of Post-Traumatic Stress Disorder (PTSD) Initial — 27.9 score on a scale
N/A N=182 Telerehabilitation in People With Long COVID
COVID-19
Primary: Change in Exercise Capacity: Peak Oxygen Uptake (VO2peak) From Baseline to 12 Weeks — 2.4; 1.7 ml/kg/min
N/A N=119 Myocardial Injury and Quality of Life After COVID-19
COVID-19 · Myocardial Injury · Myocarditis Post Infection
Primary: Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles. — 19; 39; 48 Participants
N/A N=44 Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors
Covid-19 · Deconditioning
Primary: Adherence (Primary Feasibility/Safety Outcome) — 93 % of participants meeting adherence
N/A N=20 CoV-PICS: A Virtual Post-ICU Clinic
Post ICU Syndrome
Primary: Acceptance With COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Visits - AIM — 4.8 score on a scale
N/A N=44 Swallowing Impairment After COVID-19 Infection
Covid19
Primary: Number of Participants With Impaired Swallowing Safety — 3; 1 Participants — p=<0.001
Phase 3 N=77 Homeopathic Treatment of Post-acute COVID-19 Syndrome
Post-acute Covid-19 Syndrome
Primary: Fatigue Assessment Scale (FAS) — 32.9; 31.4; 29.0; 27.4 score on a scale
Phase 1 N=19 Electrical Stimulation for Critically Ill Covid-19 Patients
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
N/A N=252 Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic
Covid19 · Critical Care · Postintensive Care Syndrome
Primary: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) — 5; 13.5 units on a scale
N/A N=17 Vagus Nerve Stimulation as Treatment for Long Covid
Long COVID · Chronic Fatigue Syndrome
Primary: Number of Participants With Treatment Success — 8 Participants
N/A N=74 Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue
Post Covid-19 Patients
Primary: Fatigue Assessment Scale (FAS) — 31.32; 28.42; 14.90; 15.3 Total score (1 to 5 point scale)
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
N/A N=21 Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention
Long COVID
Primary: Change in Functional Improvement Post-COVID-19 Over Time — 8.4; 21.05; 4.55; 6.6 score on a scale — p=.06
N/A N=23 Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
Covid19
Primary: Insulin-Like Growth Factor-1 (IGF1) — 142.8; 137.6 ng/ml
N/A N=64 Cognitive Rehabilitation in Post-COVID-19 Syndrome
Post-COVID-19 Syndrome
Primary: Recruitment Rate — 65 Participants
N/A N=18 Vagal Nerve Stimulation for Post COVID Fatigue
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Phase 3 N=22 Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Long COVID
Primary: Change in the Symptoms of Long COVID-19 Patients — 20.33; 27; 15.71; 22.43 units on a scale — p=0.200
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Phase 2 N=30 Convalescent Plasma for Patients With COVID-19
Coronavirus Infection · Coronavirus · COVID
Primary: Change in Respiratory Disease Severity — 251; 276 ratio
N/A N=1,102 Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
COVID-19
Primary: Number and Severity of Confirmed COVID-19 Infections Among Cancer Centre Staff and Patients at 12 Months — 55; 36 Participants
N/A N=2,097 COVID-19 Watch + COVID-19 Pulse
Covid19
Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days
N/A N=93 Increasing Physical Activity in COPD Through Rhythmically Enhanced Music
COPD Patients and Patients Recovering From COVID19
Primary: Six-minute Walk Distance — 452; 429 meters — p=0.85
N/A N=47 Chronic-disease Self-management Program in Patients Living With Long-COVID in Puerto Rico
Long Covid19
Primary: Assessment of the Impact of Health-related Quality of Life — 4; 3; 4; 6 Participants
N/A N=45 Mindfulness Intervention for Post-Covid Symptoms
COVID-19 · Post Acute Sequelae of SARS-CoV-2
Primary: Change in Stress — -5.0 units on a scale — p=<0.001
Phase 2 N=34 Extension Study in a Cohort of Adult Patients With COVID-19 Infection
COVID-19 Infection
Primary: Number and Percentage of Participants With Complications Related to Post COVID-19 Infection — 4; 8; 5; 17 Participants
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants